Practice

The countdown is on! ⏱️ Drs. Jack Cush & Artie Kavanaugh are previewing what’s coming to RheumNow Live 2026 in Dallas (Feb 7–8) – and you don’t want FOMO on this one. ✅ Register now at https://t.co/4UQlqwujiR 🔥Early bird pricing ends December 15 – Get the inside scoop on https://t.co/K6kxX2oDtu

Links:

Dr. John Cush @RheumNow( View Tweet )
APP QD Clinic: Difficult AxSpA Philip Mease, MD and Christy Vath, PA-C, Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/qlBUtt6zWr
Dr. John Cush @RheumNow( View Tweet )
APP QD Clinic: Unweanable PMR APP QD Clinic: Unweanable PMR Jack Cush, MD, and Leilani Law, APN, Dallas, TX, discuss a case regarding unweanable polymyalgia rheumatica. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the https://t.co/Gl8iQJf1d2
Dr. John Cush @RheumNow( View Tweet )
INITIAL Goal is to not miss Red Flag Conditions (Fx, septic or crystal arthritis [all acute monarticular})! Then provide timely Dx & Rx by establishing acute vs chronic, inflam vs noninflam, & articular vs nonarticular.

Dr. John Cush @RheumNow( View Tweet )

The Essential Role of Physician Assistants in Rheumatology Ready to bring a PA into your rheumatology practice? This blog post breaks down the key facts you need to know about PA training, scope of practice, and the recent changes to the profession's title. https://t.co/0aCTUpWMab
Dr. John Cush @RheumNow( View Tweet )
Focus on Guidelines https://t.co/Dgu0F5UiNY

Links:

Dr. John Cush @RheumNow( View Tweet )

purpura

B Cell Targeting in Idiopathic Thrombocytopenic Purpura

EurekAlert!

The New England Journal of Medicine  has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune

Read Article
RHEUM Survey> What is the goal for every new MSK patient evaluation?

Dr. John Cush @RheumNow( View Tweet )

DMARD Treatment Lags for Minority Groups with Rheumatoid Arthritis Use of disease-modifying anti-rheumatic drugs (DMARDs) for RA was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis of federal survey data indicated, https://t.co/eZOLAN4KVr
Dr. John Cush @RheumNow( View Tweet )
GESPIC - German SpA study of 252 SpA (139 nr- axSpA, 113 r-axSpA), followed w/ serial Xrays and mSASS Scores over 2 yrs. 80% were on NSAIDs. Higher NSAID intake, particularly COX2i, on slowing radiographic progression in axSpA https://t.co/MfmzWwvtZx https://t.co/5Fe2AQgkN2

Links:

Dr. John Cush @RheumNow( View Tweet )
Cochrane review of nurse-led care (NLC) in RA, included 14 articles & 3369 RA pts. NLC proves highly effective in managing RA patients, surpassing usual care and equating to rheumatologist-led care in dz activity and some secondary (self efficacy, pain, QOL) outcomes https://t.co/gd9vbcOR8P
Dr. John Cush @RheumNow( View Tweet )
JAMA Case Challenge - Painful Hand Swelling With Finger Contractures 56-yoF w/ BL hand contractures, 15 mos BL hand pain/swelling/stiffness. No or partial relief w/ ibuprofen, 30 mg prednisone, MTX 10-20 mg/wk. All labs were normal. Whats the Dx? https://t.co/lZ0NHX5Y56 https://t.co/JC04E3JUxB

Links:

Dr. John Cush @RheumNow( View Tweet )
labs.tubes_.jpg

British Society of Rheumatology Guideline for Monitoring DMARDs

Jack Cush, MD

The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic autoimmune rheumatic diseases (SARDs). 

Read Article
chain-2364830_640.jpg

The Essential Role of Physician Assistants in Rheumatology

Daric A. Mueller, PA-C

Ready to bring a PA into your rheumatology practice? This blog post breaks down the key facts you need to know about PA training, scope of practice, and the recent changes to the profession's title.

Read Article
RheumNow Live 2026 Where the data meets the dialogue. Join leading rheumatologists, researchers, and innovators at RheumNow Live 2026 — the meeting redefining rheumatology education. ➡️https://t.co/zYYC2350tE https://t.co/I7YxpEcBG6

Links:

Dr. John Cush @RheumNow( View Tweet )
"Act as if what you do makes a difference. It does." – William James

Dr. John Cush @RheumNow( View Tweet )

Hiring, Onboarding and Training APPs Watch our kickoff webinar for this month's Mission: APP — Partners in Care campaign. Our panel of rheumatologists and experienced advanced practice providers share insights into hiring, onboarding, training, compensation, and more. https://t.co/stgTQM9soW
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

APPs in the News (12.5.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salary concerns.

Read Article
QD Clinic: Flare or Beware Lindsay Tom, PA-C and Phong Nguyen, MD, Reston, VA discuss today's case called "Flare or Beware", involving a patient who has psoriatic arthritis mutilans, presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of https://t.co/JbyHBCQ4ct
Dr. John Cush @RheumNow( View Tweet )
muscle%20aches.jpg

Low Dose Naltrexone for Fibromyalgia Pain - Use it or Lose it?

Jack Cush, MD

Medscape recently reviewed off-label use of low dose naltrexone (LDN) in fibromyalgia (FM) and found it is deemed effective by some clinicians and patients, but 1) there is no FDA indication for LDN use in FM and 2) the data supporting its use is limited.

Read Article
DMARDs,biologics,RA

DMARD Treatment Lags for Minority Groups with Rheumatoid Arthritis

MedPage Today

Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis of federal survey data indicated, even after adjusting for income, education, and other factors

Read Article
Consensus Definitions on Difficult to Treat PsA A substantial number of patients with PsA, have difficult, persistent and hard-to-treat disease. A GRAPPA task force has developed a consensus terminology for two distinct states: Complex-to-manage PsA (C2M-PsA) https://t.co/po1psn9GNm
Dr. John Cush @RheumNow( View Tweet )
Long-Term APP Retention: Building Success for Practices and Providers Advanced Practice Providers (APPs) are vital in rheumatology due to rising patient numbers and the need for prompt care. Their integration enhances practice efficiency, improves patient access, and balances https://t.co/bZBkbWyWfI
Dr. John Cush @RheumNow( View Tweet )
students.studying

Changing Loan Limits for Advance Practice Providers

Jack Cush, MD

The "One Big Beautiful Bill" (OBBB), or H.R. 1, was signed into law in July, calls for significant changes in the funding of healthcare education.  This bill that lowers cap limits on education loans applies to graduate (APRN, PA) programs. It was driven by the need to lower the US

Read Article
U Colorado compared 10K Traditional Rheum consults (TC) to 670 eConsults. 75% eConsults completed without F2F eval & 73% w/in 3 days. eConsults referred to F2F had better 180d completion rates (36% vs 19% TC, p< 0.001). Dx & Rx rates were similar. Most eConsults came from PCPs. https://t.co/fE6yLMcm25
Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Evaluation of MSK cover
In this review, Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice. Read Post
rheumthought

CNS Lupus (NPSLE)

Jack Cush, MD
Cush RhTh CNS
29 yr. old woman with SLE and transverse myelitis. Is this NPSLE; how to diagnose? Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×